WebModerna. Moderna, Inc. ( / məˈdɜːrnə / mə-DUR-nə) [4] là một công ty công ty công nghệ sinh học của Mỹ có trụ sở tại Cambridge, Massachusetts, tập trung vào phương pháp điều trị RNA, chủ yếu là vắc-xin mRNA. Những vắc-xin này sử dụng một bản sao của phân tử gọi là RNA thông tin ... WebJan 10, 2012 · Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in ...
Merck to Acquire Cubist Pharmaceuticals for $102 Per …
WebBefore that, he was Chief Financial Officer at Cubist Pharmaceuticals, Inc., or Cubist, a Nasdaq-listed biopharmaceutical company. He was at Cubist from August 2010 to January 2015, through the company’s sale to Merck, and held a series of roles of increasing responsibility leading finance, investor relations and strategic sourcing. WebCubist Pharmaceuticals Inc. said last week that it had reached an agreement with Pfizer Inc. to develop and sell antibacterial drugs. The terms were not disclosed. fmj arrows 400
Cubist Pharmaceuticals LLC - Company Profile and News
Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA. . The company employed 638 people, mostly in Lexington, MA. On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion). See more Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors. Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to … See more The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with See more WebDec 9, 2003 · Company: Cubist Pharmaceuticals, Inc. Application No.: 021572 Approval Date: 9/12/2003. Approval Letter(s) (PDF) Printed Labeling (PDF) Medical Review(s) … Web$ACXP In December 2014, Merck ( $MRK) paid US$9.5 billion for Cubist ( $CBST) largely to obtain marketing access to agents daptomycin and fidaxomicin. Acurx finds itself in an eerily analogous situation, with an agent for MRSA and VRE, as well as another for C. diff. green screen photo background adder